Skip to main content
Guobang Pharma Ltd. logo

Guobang Pharma Ltd. — Investor Relations & Filings

Ticker · 605507 ISIN · CNE100004NS2 LEI · 300300PS6T4W4PGYPM51 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 510 across all filing types
Latest filing 2025-10-16 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 605507

About Guobang Pharma Ltd.

https://www.gbgcn.com

Guobang Pharma Ltd. specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and finished dosage forms. The company operates across two primary sectors: human health and animal health. Its product portfolio includes a wide range of anti-infectives, such as macrolides and quinolones, as well as cardiovascular medications and veterinary drugs like florfenicol. Guobang Pharma maintains a comprehensive industrial chain, leveraging large-scale production facilities and advanced chemical synthesis technologies to serve global markets. The organization focuses on providing integrated solutions for pharmaceutical raw materials, emphasizing quality control and regulatory compliance to meet international standards.

Recent filings

Filing Released Lang Actions
国邦医药关于选举职工代表董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of an employee representative director to the company's board. It includes details about the election process, the elected individual's qualifications, and compliance with relevant laws and regulations. There is no financial data, no mention of financial results, no report attached or referenced, and no indication of a meeting presentation or voting results announcement. This fits the category of Board/Management Information (MANG), as it concerns changes in the company's board of directors.
2025-10-16 Chinese
投资者关系管理制度（2025年10月修订）
Governance Information Classification · 95% confidence The document is titled '国邦医药集团股份有限公司 投资者关系管理制度' which translates to 'Investor Relations Management System of Guobang Pharmaceutical Group Co., Ltd.' It outlines the company's policies, principles, responsibilities, and organizational structure for managing investor relations. The content focuses on governance, communication with investors, compliance with laws and regulations, and internal procedures for investor relations management. There are no financial statements, earnings data, or specific report disclosures. The document is a governance-related policy document rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-10-16 Chinese
董事会议事规则（2025年10月修订）
Governance Information Classification · 100% confidence The document is titled '董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors'. It details the internal rules, procedures, and governance practices related to the board meetings of the company, including meeting types, proposal procedures, voting, and record-keeping. There is no financial data, audit information, or report publication mentioned. The content is focused on governance structure and board management practices. Therefore, this document fits the category of Governance Information (CGR). The document length is about 4851 characters, which is sufficient for a detailed governance document, not a brief announcement or certification.
2025-10-16 Chinese
独立董事提名人声明与承诺-潘自强
Board/Management Information Classification · 95% confidence The document is a formal statement nominating an independent director candidate for the board of a company, detailing qualifications, compliance with regulatory requirements, and declarations of independence. It does not contain financial data, audit results, or report publication information. It is related to board/management information, specifically about a board nomination and related declarations. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short and focused on nomination, not a full report or announcement of voting results.
2025-10-16 Chinese
独立董事候选人声明与承诺-孔令义
Board/Management Information Classification · 95% confidence The document is a declaration and commitment statement by an independent director candidate, detailing qualifications, compliance with laws and regulations, and independence criteria. It does not contain financial data, audit results, or report content. It is related to board/management information, specifically about a director candidate's qualifications and commitments. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on director candidacy, not a report or announcement of voting results or governance rules.
2025-10-16 Chinese
信息披露管理制度（2025年10月修订）
Governance Information Classification · 95% confidence The document is a comprehensive information disclosure management system of a company, detailing rules, responsibilities, and procedures for information disclosure, including definitions, periodic and interim reports, major event disclosures, insider trading rules, and confidentiality. It is a governance-related document outlining internal policies and compliance with regulatory requirements, rather than a financial report, earnings release, or announcement. It does not contain financial data or results but focuses on governance and disclosure management practices. Therefore, it fits best under Governance Information (CGR). The document length and detail support this classification with high confidence.
2025-10-16 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.